Viral hepatitis in the liver transplant recipient

Infectious Disease Clinics of North America

Volumn 14, Issue 3, 2000, Pages 761-784

  Rosen, Hugo R ^a,b   Martin, Paul ^c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c University of California School of Medicine   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; RECURRENT DISEASE; REVIEW; VIRUS HEPATITIS; VIRUS LOAD;

EID: 0033831446     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70130-6     Document Type: Article

References (131)

1. The interaction between hepatitis B and hepatitis C virus in acute and chronic liver disease
2. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis
3. The detection, transmission, and outcome of hepatitis C virus infection
4. The epidemiology of acute and chronic hepatitis C
5. Hepatitis C associated glomerulonephritis
6. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation
7. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
8. Long-term outcome of liver transplant recipients in the US
9. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation
10. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection
11. Antiviral therapy before and after liver transplantation
12. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
13. Long-term outcome of hepatitis C virus infection after liver transplantation
14. Interactions between alcohol and hepatitis viruses in the liver
15. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
16. HLA class I matching is responsible for the hepatic lesions in recurrent viral hepatitis B after liver transplantation
17. Recurrent hepatitis C after liver transplantation
18. Outcome of liver retransplantation for recurrent hepatitis C infection
19. Immunopathogenesis of hepatitis B virus infection
20. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
21. Predictors of patient and graft survival following liver transplantation for hepatitis C
22. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of NIDDK Liver Transplantation Database
23. Increased mortality following CMV infection in patients transplanted for HCV: Results of the NIDDK liver transplantation database
24. Quantitation of hepatitis C virus RNA in liver transplant recipients
25. 'Occult' hepatitis B virus as source of infection in liver transplant recipients
26. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
27. Cyclosporin A modulates the course of woodchuck hepatitis virus infection and induces chronicity
28. Hepatitis C virus recurrence after liver transplantation: Relationship to anti-HCV core IgM, genotype, and level of viremia
29. Severe clinical course of de novo hepatitis B infection after liver transplantation
30. Retransplantation for hepatitis B - A multicenter experience
31. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
32. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation
33. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
34. Infectivity of hepatic allografts with antibodies to hepatitis B virus
35. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient
36. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
37. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation
38. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation
39. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus
40. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
41. Hepatitis C viral infection in liver transplant recipients
42. Prevention of recurrent hepatitis B infection following liver transplantation: Experience in 112 North American patients
43. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions
44. The role of TNF-alpha in HCV recurrence following liver transplantation
45. Hepatitis C virus infection following liver transplantation
46. A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation
47. A longitudinal analysis of hepatitis C virus replication following liver transplantation
48. Long-term outcome of hepatitis C infection after liver transplantation
49. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
50. Tacrolimus versus cyclosporine immunosuppression in liver transplantation for hepatitis C
51. Do viral genotypes and HLA matching influence the outcome of recurrent hepatitis C virus infection after liver transplantation?
52. Clinical outcome of hepatitis C as a function of mode of transmission
53. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features
54. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients
55. Combination HBIG and lamivudine is both highly efficacious and cost-effective in preventing recurrent hepatitis B in orthotopic liver transplant recipients compared to HBIG monotherapy
56. Liver transplantation in Asian patients with chronic hepatitis B
57. Hepatitis B and C after transplantation
58. Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation
59. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft
60. Late hepatic artery thrombosis: A potential complication of viral hepatitis
61. Impact of donor hepatitis C infection on recipient outcome following liver transplantation in the hepatitis C positive recipient: An analysis of the UNOS data
62. Liver transplantation for chronic hepatitis B in Asians
63. Hepatitis C virus-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
64. Infrequent vertical transmission of hepatitis C virus
65. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation
66. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
67. Genetic heterogeneity of hepatitis C virus: The clinical significance of genotypes and quasispecies behavior
68. A prospective controlled trial of tacrolimus vs. cyclosporine in orthotopic liver transplant recipients with hepatitis C virus: Lack of effect on recurrent hepatitis
69. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis
70. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
71. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence
72. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro
73. Human leukocyte antigen class I-independent pathways may contribute to hepatitis B virus-induced liver disease after liver transplantation
74. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
75. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis
76. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation
77. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
78. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
79. Patterns of hepatitis delta virus reinfection and disease in liver transplantation
80. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
81. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation
82. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin in reducing the incidence of acute rejection post transplantation
83. Natural history of liver fibrosis progression in patients with chronic hepatitis C
84. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
85. Retransplantation of the liver for recurrent hepatitis B virus infection: The Paul Brousse experience
86. Cytomegalovirus viremia: Risk factor for allograft cirrhosis following liver transplantation for hepatitis C
87. Molecular epidemiology of hepatitis C infection in U.S. Veteran liver transplant recipients: Evidence for decreasing relative prevalence of genotype 1b
88. The humoral immune response to hepatitis C following liver transplantation: Assessment of a new immunoblot assay
89. Timing and severity of hepatitis C recurrence following liver transplantation as predictors of longterm allograft injury
90. Hepatitis C virus: Molecular aspects and implications for future therapy
91. Gastroenterology
92. Donor polymorphism of tumor necrosis factor gene associated with variable severity of hepatitis C recurrence following liver transplantation
93. Use of OKT3 (monoclonal antibody) associated with early and severe hepatitis C recurrence following liver transplantation
94. Hepatitis C infection in patients undergoing liver retransplantation
95. Liver transplantation
96. OKT3 and hepatitis C: Defining the risks
97. Graft loss following liver transplantation in patients with chronic hepatitis C
98. Acquisition of hepatitis C by a conjunctival splash
99. Hepatitis C for the hospital epidemiologist
100. Liver transplantation in European patients with the hepatitis B surface antigen
101. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis
102. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
103. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
104. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
105. Histological and clinical outcome after liver transplantation for hepatitis C
106. Variability of hepatitis C virus
107. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis
108. Interferon-a for prophylaxis of recurrent hepatitis C in liver transplant recipients
109. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope
110. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?
111. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: Correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns
112. Improved survival of hepatitis B patients undergoing liver transplantation: Effects independent of therapeutic interventions
113. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
114. Interferon alpha for recurrent hepatitis B infection after liver transplantation
115. Hepatitis B virus and liver transplantation
116. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro
117. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
118. Clinical outcomes after transfusion-associated hepatitis C
119. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants
120. Outcome of liver transplantation in hepatitis C virus-infected grafts
121. The influence of hepatitis C virus genotype on the outcome of liver transplantation
122. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
123. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation
124. FK506 in liver transplantation for chronic hepatitis B: In Vitro studies on lymphocyte activation and virus replication
125. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma
126. The long-term pathological evolution of chronic hepatitis C
127. Intramuscular hepatitis B immune globulin continued with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
128. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
129. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
130. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia
131. Patterns and mechanisms of hepatitis B/hepatitis D reinfection after liver transplantation